+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Radionephrographic Follow-Up with Hypertensive Patients after Angioplasty of Renal Artery Stenosis

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Radionephrographies were performed in 23 hypertensive patients before and after 28 transluminal dilatations (PTD) of their stenosed renal arteries. The changing clearances for both kidneys (global = Cl<sub>gl</sub>) and for stenosed and contralateral kidneys (Cl<sub>st</sub> and Cl<sub>co</sub>) were followed for three groups, dependent on their clinical outcome, as well as the parenchymal transit time (re-entry time) for the diseased (Rt<sub>st</sub>) and contralateral kidneys (Rt<sub>co</sub>): (A) Normalized hypertension: for 9 patients the preoperative Cl<sub>co</sub> was never lower than 150 ml/min, but increased significantly after PTD. Rt<sub>st</sub> fell significantly, Rt<sub>co</sub> remained constant. Mean increase in Cl<sub>gl</sub> = 91 ml/min (+25%). (B) Improved hypertension: in 12 patients Cl<sub>st</sub> and Cl<sub>co</sub> had been lower than with those in group A; postoperatively Cl<sub>st</sub> increased, Rt<sub>st </sub>fell significantly. The Rt<sub>co</sub> was prolonged early after PTD but normalized later. (C) Permanent hypertension: for 7 of these patients there were no preoperative criteria for a discrimination against the other groups. But in all Rt<sub>st</sub> did not normalize, and Rt<sub>co</sub> increased early after PTD. Even in later examinations Rt<sub>co</sub> remained higher than preoperatively. These results imply that the success of PTD depends mainly on the behavior of the contralateral kidney. The examination 1 day after the PTD gives an optimal prognosis concerning the end result.

          Related collections

          Author and article information

          S. Karger AG
          11 November 2008
          : 72
          : Suppl 1
          : 13-21
          Departments of aNuclear Medicine and bMedical Clinics, University Hospital, Bern, Switzerland
          173939 Cardiology 1985;72:13–21
          © 1985 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 9


          Comment on this article